Quantum BioPharma Ltd. (QNTM)
NCM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company's lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. It also develops FSD-PEA, which is in preparation for Phase 2 trial for the treatment of inflammatory diseases, such as mast cell activation syndrome; Lucid-PSYCH to treat major depressive disorder; and unbuzzd, a dietary supplement for the treatment of alcohol misuse. In addition, the company maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd. was founded in 1998 and is based in Toronto, Canada.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
UWI appoints new CEO to guide unbuzzd national commercial expansion
# 📋 What This Document Is 📰 This filing is a Form 6-K, which is a public report used by international companies to announce material, significant events to U.S. investors. 📈 Essentially, it serves as a major corporate announcement regarding the strategic direction, leadership changes, and commerc
Quantum Biopharma Ltd. — 6-K Filing
# 🔥 What This Document Is This is a 6-K filing, which is a **current report** that public companies use to announce major events to shareholders. It contains a **press release** announcing a significant legal victory for Quantum Biopharma. In simple terms, a court has allowed their massive $700 mi
Quantum Biopharma Ltd. — 6-K Filing
# 🧾 What This Document Is This is a **6-K report**, a filing foreign companies use with the SEC to share major news with investors. This specific filing contains a **press release** announcing a major regulatory milestone for their drug candidate. Think of it as an official update to the market on
March 2026
Quantum Biopharma Ltd. — 6-K Filing
# 🧾 What This Document Is This is a **6-K filing**, which is a report foreign companies (like Canadian-based Quantum) must submit to the SEC to share important news with U.S. investors. Specifically, it's a **press release** announcing a major new partnership to run a clinical trial for their main
SEC filings
All filings →Insider trades
All insider trades →Quantum BioPharma Ltd. has no reported insider trades in the last 90 days.
Institutional holders
All holders →People at Quantum BioPharma Ltd.
All people →No officers or directors have been indexed for Quantum BioPharma Ltd..